Ongentys opicapone regulatory update

The European Commission approved Ongentys opicapone from Bial-Portela as an adjunctive therapy to levodopa/ dopa decarboxylase (DDC; AADC) inhibitors in adults with Parkinson’s disease (PD) and end-of...